On a water-soluble powder packaging line for poultry, Wengbai Jiedu Powder veterinary-grade API is first delumped through a 60-mesh rotary sifter and dried to ≤ 5.0% moisture before carrier dilution. The sifted fraction is pre-blended at 1:5 with anhydrous dextrose monohydrate in a 500 L ribbon blender running at 12 rpm for 8 min; geometric dilution then brings the API to the labelled concentration. A second blending stage with sodium citrate 0.5–1.5% w/w adjusts the reconstituted solution pH to 6.5–7.5, because acidic farm water below pH 5.0 causes immediate precipitation of the water-insoluble triterpene fraction. The blend is discharged through a 1.0 mm mesh and packed into 100 g PET/Al/LDPE pouches at 145–160 °C seal temperature. For field use, a 1 g/L reconstitution in drinking water must pass a 180 µm wet sieving test without visible flakes. The product is assigned a 24 h in-use stability limit at 25 °C after reconstitution, beyond which microbial growth in drinker lines becomes the controlling risk. A typical finished powder contains 5–20% w/w API, with the remainder being water-soluble carrier, citric acid or sodium bicarbonate effervescent pairs, and 0.2% w/w anti-caking silicon dioxide. Compliance for the line follows EU Regulation 2019/6 for veterinary medicinal products, and good manufacturing practice requirements under 21 CFR Part 211 when exported into regulated markets.

What Happens When a Botanical Powder Enters Continuous Medicated Feed Premix Lines at 2 kg/t Inclusion?

At 2 kg/t inclusion in a swine or poultry feed premix, the powder API is first dispersed onto a carrier because direct metering into a continuous mixer produces assay coefficient of variation above 12%. Spray-dried corn starch and rice hulls with particle size 150–400 µm are preferred. The carrier is charged into a 1 t horizontal paddle mixer at 55–60 rpm, and the API is pre-mixed with 10 kg of carrier for 5 min before the remaining carrier is added. Mixing continues for 10–12 min; ten sampling points across the discharge stream must show assay CV ≤ 5.0%. A volumetric screw feeder with 1–2% feed rate drift is unacceptable for final top-dress applications, so checkweigher feedback or gravimetric loss-in-weight feeding is used. Dust containment at the blender loading port is required because the API fines below 45 µm remain airborne for more than 30 s and create cross-batch carryover. The finished premix is bagged at 20 kg with one desiccant sachet, and total moisture is held ≤ 8.0%. Storage above 30 °C or at relative humidity greater than 60% causes caking and assay loss of the water-soluble marker compounds. Good manufacturing practice for medicated feed premix operations is assessed against 21 CFR Part 225 in the United States, while feed safety systems follow ISO 22000:2018 and EU feed hygiene requirements under Regulation (EC) No 183/2005.

Segregation is the dominant failure mode when the premix is discharged into silos. The API particle size must be reduced to D90 ≤ 125 µm and the particle size ratio between API and carrier kept below 3:1. If the carrier is too large above 600 µm, the active fraction sifts to the bottom during pneumatic transfer. A simple sifter test after conveying through a 15 m pipe at 3 bar air pressure should show no more than 5% difference in assay from top to bottom. The end product is a 20 kg premix bag for on-farm feed mixing, typically diluted 1:100 to 1:200 into final feed. This scenario is considered deep-dive because the processing window for moisture is narrow: below 4.0% moisture static charge increases, while above 8.0% microbial risk and caking rise sharply.

Direct compression of the API at loadings above 20% w/w is not practical on production rotary presses. The powder exhibits bulk density 0.30–0.40 g/mL, angle of repose above 35°, and compressibility index above 25%, causing die fill variation and tablet weight CV above 5.0%. Wet granulation is therefore used for cattle boluses. The API is combined with microcrystalline cellulose 20–30%, dibasic calcium phosphate 5–10%, and polyvinylpyrrolidone K30 3–5% dissolved in purified water. The wet mass is kneaded in a planetary mixer for 10–15 min, extruded through a 10 mesh screen, and dried in a fluid-bed dryer at 55–60 °C until granule moisture is ≤ 3.5%. The dried granules are milled through a 1.0 mm screen and lubricated with sodium stearyl fumarate 1.0–1.5% rather than magnesium stearate alone, because prolonged blending with magnesium stearate above 5 min can reduce tablet hardness by more than 15%. Compression on a 27-station rotary press uses pre-compression 4–6 kN and main compression 18–28 kN. The resulting 5 g or 10 g bolus tablet has hardness 90–150 N, friability ≤ 1.0%, and disintegration time ≤ 15 min when tested by Ph. Eur. 2.9.1 in water at 37 ± 2 °C. Assay uniformity is evaluated by USP <905> with acceptance value ≤ 15. Tool sticking is seen when relative humidity exceeds 55% during compression; dehumidified rooms at 40–50% RH and polished hardened-steel tooling reduce the defect rate to below 1%.

When Capsule Filling Encounters Low Bulk Density Extract Above 65% RH

Ambient relative humidity above 65% during capsule filling turns the spray-dried API into a cohesive mass even when the measured moisture is 4.5%. The powder gains 1.5–2.0% moisture within 20 min of exposure, increasing the angle of repose beyond 40° and causing tamping-pin compression cycles to produce soft plugs or empty capsule halves. The filling sequence is therefore dry-granulated before encapsulation. The API is compacted on a roller compactor with roll pressure 20–30 kN, granulated through 0.8 mm mesh, and blended with 1.0% L-leucine and 0.5% sodium stearyl fumarate. The resulting granule has bulk density 0.55–0.65 g/mL and flow function coefficient above 4. Encapsulation is run on a 150,000 capsule/h machine with tamping-pin settings at 4 mm penetration and fill weight target 350 mg ± 5% for size 0 hydroxypropyl methylcellulose capsules. The capsule room is held at 20–25 °C and 45–50% RH; excursions above 55% RH stop the line. Dissolution testing uses USP <711> apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid for the first 60 min, followed by phosphate buffer pH 6.8. Release of the water-soluble marker fraction is not less than 80% in 60 min. Gelatin shells are not used in high-humidity markets because they become brittle below 40% RH and soften above 60% RH; HPMC shells are selected instead. The end product is a 0.35 g capsule for small ruminant or companion animal dosing, packaged in PVC/PVDC/foil blisters.

Injection-Grade Depyrogenation and Submicron Filtration for Parenteral Solutions

Aqueous dissolution of the API for parenteral use begins in a jacketed stainless vessel with water for injection at 25–35 °C. The powder is added under low-shear agitation at 300 rpm; high shear above 800 rpm creates stable foam from saponins and increases protein-polysaccharide haze. The solution is adjusted to pH 6.5–7.0 with 0.1 N sodium hydroxide or phosphate buffer, since pH values below 4.0 precipitate the acid-insoluble fraction and clog the sterilizing filter. Activated carbon at 0.1% w/w is added for endotoxin and colored impurity removal, stirred for 30 min at 55–60 °C, and removed by depth filtration through a 1–5 µm polypropylene cartridge. The solution is then passed through a 0.45 µm polyvinylidene fluoride membrane followed by a 0.22 µm sterilizing-grade polyvinylidene fluoride membrane. Bacterial endotoxins are controlled to ≤ 0.5 EU/mL by USP <85>; if the carbon treatment fails to clear endotoxin, a positively charged nylon 0.2 µm filter is inserted upstream of the sterilizing filter. The final solution is filled into 100 mL Type II amber glass vials under Grade A laminar flow, sparged with nitrogen, and closed with coated butyl rubber stoppers. Terminal moist-heat sterilization at 121 °C for 15 min is not automatically assigned to this botanical extract: published data for this specific configuration is limited, and saponin degradation may exceed 10% after terminal sterilization. Therefore aseptic filtration is the default route until forced-degradation studies confirm thermal stability. Particulate matter must meet USP <788> for large-volume parenterals if the administered volume exceeds 100 mL. The finished injection is stored at 2–8 °C; precipitation at low temperature is reversible only after warming to 25 °C and gentle inversion for 10 min. This injectable format is used for individual animal treatment where oral dosing is refused or systemic absorption is required.

Fluid bed granulation changes the particle size distribution of the API from a fine spray-dried powder to free-flowing granules suitable for oral drenching or top dressing. The granulating liquid is purified water containing hydroxypropyl cellulose 2.0–3.0% w/w or sodium carboxymethylcellulose 0.5–1.0% w/w. The API is loaded into a top-spray fluid-bed granulator with a 5 kg batch size. Inlet air temperature is set to 60–70 °C, product temperature to 35–42 °C, atomizing air pressure to 1.5–2.0 bar, and spray rate to 50–80 g/min. The end point is reached when granule moisture drops to ≤ 3.0% and the product bed temperature stabilizes near 42 °C. The granules are screened through 850 µm and 250 µm sieves; the yield between these meshes is normally above 85%. Bulk density rises from 0.35 g/mL to 0.48–0.55 g/mL. The finished granules are filled into 5 g and 25 g foil sachets with desiccant. For field use, a 2 g dose in 200 mL water at 25 °C must disperse without visible lumps within 3 min under gentle swirling. The critical process limit is the spray rate; spray rates above 80 g/min on a 5 kg batch produce uncontrolled agglomeration above 1.2 mm and uneven API distribution. This granulated format is preferred for sheep, goats, and calves when the target dose is 0.5–2.0 g of API per animal per day.

Oral Solution Concentrate Stability and Polysaccharide Precipitation Limits

Multi-dose oral solution concentrate for calves and pigs is prepared by dispersing the API at 5–10% w/v in a co-solvent system of propylene glycol and purified water, typically 30:70 v/v. Propylene glycol above 40% v/v increases viscosity beyond 30 mPa·s at 25 °C and slows pouring from 1 L HDPE bottles in cold barn conditions. The solution is adjusted to pH 6.5–7.5 with trisodium citrate or sodium hydroxide. Sodium benzoate 0.1% w/w and potassium sorbate 0.1% w/w are added as preservatives in multi-dose containers. The liquid is clarified through a 10 µm nylon bag filter, then filled into amber HDPE bottles with tamper-evident caps and dosing chambers. At 4 °C, the solution may become turbid or form a sediment because high-molecular-weight polysaccharides precipitate; the limit is set at ≥ 15 °C for storage and transport. Before administration, the bottle is warmed to 25 °C and inverted 5–10 times to redisperse any sediment. In-use stability is limited to 28 days after opening. The critical incompatibility is with mineral acids and strongly saline solutions above 0.9% sodium chloride; mixing with oral rehydration salts can cause immediate flocculation. The end product is a 1 L oral solution concentrate for herd-level administration through water proportioners or drenching guns.